Lauren E. Damon - Concepedia

Author

Lauren E. Damon

University of California, San Francisco ORCID

Also Known As

L E Damon, L. Damon, L. E. Damon, L.E. Damon, Lauren Damon, Lauren E Damon, Lauren E. Damon, Lauren Elizabeth Damon

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco University of Pennsylvania UCSF Helen Diller Family Comprehensive Cancer Center Cancer Research Institute Icahn School of Medicine at Mount Sinai

About

Lauren E. Damon is an author at University of California, San Francisco specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	964
2	Health Sciences	2	2	794
3	Public Health	1	1	109
4	Cell Biology	1	1	734
5	General Surgery	1	1	17

Lauren E. Damon

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Catherine C. Smith, Qi Wang, Chen-Shan Chin, Nature Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2012	734
Crenolanib is a selective type I pan-FLT3 inhibitor Catherine C. Smith, Elisabeth A. Lasater, Kimberly C. Lin, Proceedings of the National Academy of Sciences	2014	207
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397 Catherine C. Smith, Chao Zhang, Kimberly C. Lin, Cancer Discovery	2015	197
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Blood	2013	127
Increased CD62e+ Endothelial Microparticle Levels Predict Poor Outcome in Pulmonary Hypertension Patients Nicolas Amabile, Vivian Y. Chang, Franca S. Angeli, The Journal of Heart and Lung Transplantation Endothelial Cell PathobiologyHypertensionPulmonary Arterial HypertensionPulmonary CirculationCardiovascular Disease	2009	109
High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. G. Adair Smith, Lauren E. Damon, Hope S. Rugo, Journal of Clinical Oncology	1997	91
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 Hui Liu, Jeffrey L. Johnson, Greg Koval, Haematologica	2011	77
The association between high-dose cytarabine neurotoxicity and renal insufficiency. Lauren E. Damon, R. Mass, Claudia Linker Journal of Clinical Oncology Renal PathologyPharmacotherapyCreatinine ClearancesHematological MalignancyHematology	1989	60
Cytotoxicity of ketoconazole in malignant cell lines Christoph Rochlitz, Lauren E. Damon, M Russi, Cancer Chemotherapy and Pharmacology OncologyMedicineMalignant Cell LinesAnti-cancer AgentPharmacology	1988	44
Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants Catherine C. Smith, Elisabeth A. Lasater, Melissa Q. McCreery, Blood	2012	18

Page 1